Healthcare Industry News: Novartis Oncology
News Release - June 5, 2017
Bayer Expands Oncology Organization with Two New Leadership Team AppointmentsWHIPPANY, N.J., June 5, 2017 -- (Healthcare Sales & Marketing Network) -- Bayer today announced the recent appointments of Rebecca Jolley as senior vice president and commercial head, Oncology and Dr. Scott Z. Fields, senior vice president and pharmaceutical development head, Oncology. Both are members of the Oncology Leadership Team and report to Robert LaCaze, executive vice president and head of the Oncology Strategic Business Unit.
Previously, Jolley served as senior vice president, Americas Commercial, Oncology Business Group at Eisai, where she was responsible for leading the Oncology commercial strategy and implementation across all approved products and pipeline assets. Prior to joining Eisai, she worked at Novartis for more than two decades in a variety of roles of increasing responsibility, including sales, market access, marketing, brand leadership and general management. She started her career with Novartis in the UK, then transferred to the U.S. to join Novartis Oncology, where she led launches in breast cancer, pancreatic cancer, rare diseases and cancer supportive care and gained leadership experience in a variety of disciplines across a number of regions. She holds a degree in geography and biological sciences from Lancaster University, England.
Scott Fields, M.D., joined from Vertex Pharmaceuticals, where he was vice president and head of Clinical Oncology and responsible for the global development of all oncology assets. Prior to joining Vertex, he held a number of leadership roles within the pharmaceutical industry at Smithkline Beecham, Amgen, Eisai and Arno and gained experience as a practicing oncologist in academic settings. He earned his medical degree from SUNY Downstate and did his Internal Medicine and Hematology/Oncology training at Columbia University Medical Center.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.us.
© 2017 Bayer
BAYER® and the Bayer Cross are registered trademarks of Bayer.
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.